Quality of Life Analysis in Patients With RAS Wild‐Type Metastatic Colorectal Cancer Treated With First‐Line Cetuximab Plus Chemotherapy
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Colorectal Cancer"
DOI: 10.1016/j.clcc.2016.07.017
Abstract: Micro‐Abstract The present exploratory and descriptive retrospective analysis assessed the quality of life (QoL) of CRYSTAL study patients with RAS wild‐type (wt) metastatic colorectal cancer (mCRC). Our data suggest that adding cetuximab to first‐line FOLFIRI… read more here.
Keywords: first line; analysis; colorectal cancer; cetuximab ... See more keywords
Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2019 at "Asia-Pacific Journal of Clinical Oncology"
DOI: 10.1111/ajco.13154
Abstract: The open‐label, nonrandomized, phase II APEC study enrolled 167 patients with RAS wild‐type (wt) metastatic colorectal cancer (mCRC) to investigate the safety and efficacy of first‐line, every‐2‐weeks cetuximab plus investigator's choice of FOLFIRI or FOLFOX… read more here.
Keywords: phase apec; metastatic colorectal; ras wild; type metastatic ... See more keywords